Novo Nordisk Boston Consulting Group Matrix

Novo Nordisk's GLP-1 based treatments are the company's stars, holding a dominant 62% of the global market. This strong position is fueled by the rapid expansion of the GLP-1 market itself, which is expected to surge to USD 324.5 billion by 2035, growing at a compound annual growth rate of 17.3% from 2025 to 2035.

This impressive market share and growth trajectory are directly attributable to Novo Nordisk's extensive portfolio, which effectively addresses both diabetes and obesity. These therapies represent the company's core high-growth, high-market-share segment, solidifying their leadership in this critical therapeutic area.

Novo Nordisk's GLP-1 based treatments, particularly semaglutide products like Ozempic and Wegovy, are undeniably its Stars in the BCG Matrix. These products exhibit high market share in rapidly growing markets, demonstrating exceptional performance and significant future potential.

Wegovy's sales more than doubled in 2024 to DKK 58.2 billion, capturing a 70.4% volume share in the obesity market. Ozempic, a key driver of GLP-1 revenue, saw a 22% increase in constant exchange rate sales in 2024 and held 37.3% of the global GLP-1 market by 2025. Rybelsus, the oral semaglutide, secured a two-thirds share of India's GLP-1 market by July 2025, with further expansion planned.

The expanded indications for semaglutide, including cardiovascular risk reduction for Wegovy and kidney protection highlighted by the FLOW trial for Ozempic, further solidify its Star status. These advancements tap into vast, underserved patient populations, significantly increasing market potential and reinforcing Novo Nordisk's leadership.

Norditropin, a cornerstone of Novo Nordisk's rare endocrine disorder offerings, saw its segment sales climb by 14% in the first quarter of 2025. This performance underscores its status as a reliable cash generator for the company.

Operating within a niche yet stable market, Norditropin benefits from Novo Nordisk's established dominance. Its consistent revenue stream, a hallmark of a cash cow, contrasts with the more volatile, high-growth areas like obesity and GLP-1 diabetes treatments.

Novo Nordisk's established insulin portfolio, including brands like Tresiba and NovoRapid, along with Victoza, are prime examples of their Cash Cows. These products, while experiencing slower growth, generate substantial and consistent revenue streams, contributing significantly to the company's financial stability. Their mature market positions and established patient bases ensure a predictable income, allowing Novo Nordisk to invest in newer, high-growth areas.

* Specific sales figures for individual established products are not always broken out in quarterly reports, but their segment performance indicates their Cash Cow status.

These are products in highly specialized markets that haven't seen much growth or are even losing sales. They often demand a lot of money to invest but don't bring in much profit in return. While Novo Nordisk doesn't specifically call out these underperformers, they would be the products at the very bottom of their offerings, requiring careful consideration for divestment or repositioning.

Products classified as dogs within Novo Nordisk's portfolio are those with low market share in slow-growing or declining markets. These often represent older formulations or treatments that have been superseded by more advanced therapies. For instance, older insulin products that are no longer the first-line treatment option would fit this description, requiring minimal investment and generating little profit.

These underperforming assets, while not explicitly labeled as dogs, are characterized by their stagnant or decreasing sales figures and the need for continued, albeit minimal, support. Their presence in the portfolio signifies a strategic decision to maintain presence in certain segments or a phase of gradual phase-out. By 2024, Novo Nordisk's strategic focus on its blockbuster GLP-1 drugs means that resources are increasingly being diverted from these less promising areas.

The financial reality for these "dog" products is a low return on investment, often just covering their operational costs. They might still serve a niche patient population or be part of a broader therapeutic offering, but their growth potential is virtually non-existent. Companies like Novo Nordisk continually evaluate such assets, considering divestment or a complete withdrawal if they no longer align with strategic objectives or market dynamics.

Novo Nordisk's commitment to innovation in areas like obesity and diabetes means that products not contributing to this growth are prime candidates for re-evaluation. For example, if an older insulin product saw a 5% decline in sales in 2024 due to market shifts, it would be a clear indicator of its dog status, prompting a review of its future within the company's pipeline.

The 25 mg oral semaglutide, a higher-dose formulation, is positioned as a potential star in Novo Nordisk's BCG matrix. Its recent filing for US regulatory approval signals a strong likelihood of market entry, suggesting significant future growth and market share potential.

If approved, this higher-dose oral semaglutide could revolutionize the oral GLP-1 market, particularly if it gains approval for obesity treatment. This expansion offers a convenient, high-growth opportunity for Novo Nordisk.

Novo Nordisk's early-stage pipeline assets, such as CagriSema, injectable amycretin, and the tri-agonist, are prime examples of question marks. These products are in development for high-growth markets like obesity and metabolic diseases, but they currently have no market share and consume significant resources. Their future success hinges on continued clinical development and regulatory approval, making them speculative but potentially high-reward investments.

The company's investments in these emerging treatments reflect a strategic bet on future market leadership. For instance, CagriSema's successful trial conclusion in Q1 2025 positions it for a 2026 regulatory submission, targeting a market projected to reach billions by 2030. Similarly, amycretin and the tri-agonist are in early development, indicating a long-term vision for these therapeutic areas.

These question marks represent opportunities for Novo Nordisk to expand its dominance in metabolic health. While they require substantial capital for research and development, their potential to capture significant market share in rapidly expanding sectors makes them crucial components of the company's growth strategy. Their classification as question marks underscores the inherent uncertainty but also the significant upside potential.